# US 2015/0147334 A1 · Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147334 A1
- Document ID: US20150147334A1
- Status: Published application
- Kind: A1
- Application number: 14/616,300
- Filed: 2015-02-06
- Published: 2015-05-28
- Earliest claimed: 2009-05-05
- Assignees: New York University
- Inventors: Thomas M. Wisniewski; Fernando Goni
- Web page: https://patentgrep.com/patent/US20150147334A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 39/0007: {Nervous system antigens; Prions}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07K 16/18: against material from animals or humans
- A61K 2039/55505: {Inorganic adjuvants}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2319/70: containing domain for protein-protein interaction
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

An isolated antibody or binding portion thereof having antigenic specificity for an epitope of a polymerized peptide, wherein the polymerized peptide is selected from the group consisting of:
a polymer of a first peptide comprising the amino acid sequence X1aX2aX3aX4aX5aX6aX7aX8aX9aX10aX11aX12aX13a (SEQ ID NO: 19), wherein X1a is C, M, S, or G; X2a is T, S, or C; X3a is K, R, or H; X4a is S, T, or C; X5a is V, I, or L; X6a is R, K, or H; X7a is R, K, or H; X8a is Q or N; X9a is L, I, or V; X10a is L, I, or V; X11a is D or E; X12a is D or E; X13a is Q or N;
a polymer of a second peptide comprising the amino acid sequence X1bX2bX3bX4bX5bX6bX7bX8bX9bX10bX11bX12bX13b (SEQ ID NO: 20), wherein X1b is C, M, S, Or G; X2b is F, Y, Or W; X3b is Q or N; X4b is I, L, or V; X5b is F, Y, or W; X6b is I, L, or V; X7b is Q Or N; X8b is T, S, or C; X9b is N or Q; X10b is D or E; X11b is R, K, or H; X12b is H, R, or K; X13b is Y, W, or F; and
a polymer of a fusion peptide comprising the first and/or second peptides.

### Claim at position 3

26-27. (canceled)

### Claim 28 (depends on 25)

A method of treating a condition mediated by an amyloidogenic protein or peptide in a subject, said method comprising:
administering to the subject the antibody or binding portion thereof of claim 25 in an amount effective to treat the condition mediated by the amyloidogenic protein or peptide in the subject.

### Claim at position 5

29-30. (canceled)

### Claim 31 (depends on 25)

A method of diagnosing an amyloid disease in a subject, said method comprising:
detecting, in the subject, the presence of an amyloidogenic protein or peptide using a diagnostic reagent, wherein the diagnostic reagent comprises the antibody or binding fragment thereof of claim 25, and
diagnosing an amyloid disease in the subject based on said detecting.

### Claim at position 7

32-34. (canceled)

### Claim 35

An isolated first peptide comprising the amino acid sequence of X1aX2aX3aX4aX5aX6aX7aX8aX9aX10aX11aX12aX13a (SEQ ID NO: 19), wherein X1a is C, M, S, or G; X2a is T, S, or C; X3a is K, R, or H; X4a is S, T, or C; X5a is V, I, or L; X6a is R, K, or H; X7a is R, K, or H; X8a is Q, or N; X9a is L, I, or V; X10a is L, I, or V; X11a is D or E; X12a is D or E; X13a is Q or N, with the proviso that the isolated first peptide does not have an amino acid sequence of SEQ ID NO:2.

### Claim 36 (depends on 35)

The isolated first peptide of claim 35, wherein the isolated first peptide comprises the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:5.

### Claim 37 (depends on 35)

An isolated polynucleotide encoding the isolated peptide of claim 35.

### Claim 38 (depends on 37)

The isolated polynucleotide of claim 37, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 4 or SEQ ID NO:6.

### Claim 39 (depends on 37)

A recombinant vector comprising the isolated polynucleotide of claim 37.

### Claim 40 (depends on 39)

A host cell comprising the recombinant vector of claim 39.

### Claim 41

An isolated second peptide comprising the amino acid sequence X1bX2bX3bX4bX5bX6bX7bX8bX9bX10bX11bX12bX13b (SEQ ID NO: 20), wherein X1b is C, M, S, or G; X2b is F, Y, or W; X3b is Q or N; X4b is I, L, or V; X5b is F, Y, or W; X6b is I, L, or V; X7b is Q or N; X8b is T, S, or C; X9b is N or Q; X10b is D or E; X11b is R, K, or H; X12b is H, R, or K; X13b is Y, W, or F, with the proviso that the isolated second peptide does not have an amino acid sequence of SEQ ID NO:8

### Claim 42 (depends on 41)

The isolated second peptide of claim 41, wherein the isolated second peptide comprises the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:11.

### Claim 43 (depends on 41)

An isolated polynucleotide encoding the isolated peptide of claim 41.

### Claim 44 (depends on 43)

The isolated polynucleotide of claim 43, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 10 or SEQ ID NO:12.

### Claim 45 (depends on 43)

A recombinant vector comprising the isolated polynucleotide of claim 43.

### Claim 46 (depends on 45)

A host cell comprising the recombinant vector of claim 45.

### Claim 47

An isolated fusion peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:15, and SEQ ID NO:17.

### Claim 48 (depends on 47)

An isolated polynucleotide encoding the isolated fusion peptide of claim 47.

### Claim 49 (depends on 48)

The isolated polynucleotide of claim 48, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:16, and SEQ ID NO:18.

### Claim 50 (depends on 48)

A recombinant vector comprising the isolated polynucleotide of claim 48.

### Claim 51 (depends on 50)

A host cell comprising the recombinant vector of claim 50.
